false
0000883107
0000883107
2026-10-02
2026-10-02
iso4217:USD
xbrli:shares
iso4217:USD
xbrli:shares
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): October 2, 2026 (September 29, 2026)
SOLESENCE, INC.
(Exact name of registrant as specified in its charter)
| Delaware |
|
0-22333 |
|
36-3687863 |
| (State or other |
|
(Commission |
|
(IRS Employer |
| jurisdiction of |
|
File Number) |
|
Identification No.) |
| incorporation) |
|
|
|
|
1319 Marquette Drive
Romeoville, Illinois 60446
(Address of Principal Executive Offices) (Zip Code)
(630) 771-6708
(Registrant’s telephone number, including
area code)
Not applicable
(Former name or former address, if changed since
last report)
_______________________________
Check the appropriate box below if the Form 8-K filing is intended
to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
| ☐ |
Written communications pursuant to Rule 425 under the Securities
Act (17 CFR 230.425) |
| ☐ |
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
| ☐ |
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange
Act (17 CFR 240.14d-2(b)) |
| ☐ |
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange
Act (17 CFR 240.13e-4(c)) |
Securities registered pursuant to Section 12(b) of the Act:
| Title of each class |
Trading
Symbol(s) |
Name
of each exchange on which registered |
| Common
Stock, $0.01 par value per share |
SLSN |
The NASDAQ Stock
Market LLC |
Indicate by check mark whether the registrant is an emerging growth company
as defined in Rule 405 of the Securities Act of 1933 or Rule 12b-2 of the Securities Exchange Act of 1934.
Emerging growth company ☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use
the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a)
of the Exchange Act. ☐
| Item 3.01 |
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or
Standard; Transfer of Listing |
On September 29, 2026, Solésence, Inc. (the
“Company”) received a written notice (the “Notice”) from the Listing Qualifications Department of Nasdaq Stock
Market (“Nasdaq”) indicating that, because the closing bid price for the Company’s common stock has fallen below $1.00
per share for 30 consecutive trading days, the Company was no longer in compliance with the $1.00 Minimum Bid Price requirement set forth
in Nasdaq Listing Rule 5550(a)(2) for continued listing on The Nasdaq Capital Market (the “Bid Price Requirement”).
The Notice has no immediate effect on the listing of
the Company’s common stock on The Nasdaq Capital Market and does not affect the Company’s reporting requirements with the
Securities and Exchange Commission. Pursuant to Nasdaq Marketplace Rule 5810(c)(3)(A), the Company has been provided with a compliance
period of 180 calendar days, or until March 29, 2027, to regain compliance with the Bid Price Requirement (the “Initial Compliance
Period”). To regain compliance, the closing bid price of the Company’s common stock must meet or exceed $1.00 per share for
a minimum of 10 consecutive trading days prior to March 29, 2027.
If the Company does not regain compliance by March
29, 2027, the Company may be eligible for an additional grace period. To qualify, the Company must, as of the final day of the Initial
Compliance Period, meet the applicable market value of publicly held shares requirement for continued listing and all other applicable
standards for initial listing on the Capital Market (except the Bid Price Requirement) based on the Company's most recent public filings
and market information and must notify Nasdaq of its intent to cure this deficiency. If the Company meets these requirements, the Nasdaq
staff would be expected to grant an additional 180 calendar days for the Company to regain compliance with Bid Price Requirement.
The Company is currently evaluating various courses
of action to regain compliance with the Bid Price Requirement. There can be no assurance that the Company will regain compliance with
the Bid Price Requirement during the 180-day compliance period ending March 29, 2027, secure an extension of the compliance
period beyond March 29, 2027 or maintain compliance with any other Nasdaq listing requirement.
Forward-Looking Statements
This Current Report on Form 8-K contains certain forward-looking
statements within the meaning of federal securities laws with respect to the Company. Forward-looking statements are predictions, projections,
and other statements about future events based on current expectations and assumptions and, as a result, are subject to risks and uncertainties.
Many factors could cause actual future events to differ materially from the forward-looking statements in this communication, including
but not limited to: our ability to cure any deficiencies in compliance with the Bid Price Requirement or maintain compliance with other
Nasdaq Listing Rules; our eligibility for additional compliance periods, if necessary, in which to seek to regain compliance with the
Bid Price Requirement; our ability to ultimately obtain relief or extended periods to regain compliance from Nasdaq, if necessary, or
to meet applicable Nasdaq requirements for any such relief or extension; and risks related to the substantial costs and diversion of personnel’s
attention and resources due to these matters. While we are planning to take actions to address non-compliance with the Bid Price Requirement,
and have at least 180 days to do so, there can be no assurance that compliance will be achieved. Such non-compliance or a delisting from
Nasdaq would materially and adversely affect our ability to raise capital and our financial condition and business. Forward-looking statements
speak only as of the date they are made. Readers are cautioned not to put undue reliance on forward-looking statements, and, except as
required by law, the Company assumes no obligation and does not intend to update or revise these forward-looking statements, whether as
a result of new information, future events, or otherwise.
Item 9.01. Financial Statements and Exhibits.
(d) Exhibits.
| Exhibit No. |
|
Description |
| 104 |
|
Cover Page Interactive Data File (embedded within the Inline XBRL document). |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant
has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
Dated: October 2, 2026
| |
SOLÉSENCE, INC. |
| |
|
| |
|
| |
By: |
/s/ Laura Riffner |
| |
|
Name: Laura Riffner |
| |
|
Title: Chief Financial Officer |
